ACTIVE

AgomAb Therapeutics

Export PDF

Financial year 2025 · closed on 31/12/2025

Net result

-9,6 M €

+17.9% YoY

Equity

244,1 M €

-3.8% YoY

Workforce

52,0 ETP

+27.1% YoY

What does AgomAb Therapeutics do?

AgomAb Therapeutics is a Public limited company incorporated in 2017. Its main activity is: Technical testing and analysis. Its registered office is in Antwerpen. It employs on average 52,0 ETP workers (FTE).

Legal situation

● Normal situation

BCE/KBO no. / VAT

BE 0674.527.310

Incorporation

13/04/2017

Legal form

Public limited company

Registered office

Posthoflei 1 box 6
2600 Antwerpen · FlandreSee on map

Contributed capital

299 705 388,00 €

Latest accounts

31/12/2025

Average workforce

52,0 ETP

Activities (NACE)

71209Technical testing and analysis· main 71209Technical testing and analysis 72101Research and experimental development on natural sciences and engineering 72110Research and experimental development on biotechnology 72101Research and experimental development on natural sciences and engineering 72109Research and experimental development on natural sciences and engineering+2

Joint committees (1)

20700

Signals

Solid equityLow riskGood liquidityPositive cashflowHealthy social debts

View the BCE/KBO Public Search record →

Health score

Available with a Rovalta subscriptionTry for 7 days

Recommended credit limit

✦ Verdict · Analyst summary

Financials

Trend over 8 financial years

	2025		2024		2023		2022		2021		2019		2018		2017
Income statement
Gross margin	–		4,0 M €	+168%	1,5 M €	+48.7%	993,2 k €	+119%	-5,3 M €	-84.4%	-2,9 M €	-635%	-392,9 k €	-237%	-116,6 k €
EBITDA	-2,3 M €	+48.4%	-4,5 M €	-44.5%	-3,1 M €	-77.7%	-1,7 M €	+73.1%	-6,5 M €	-110%	-3,1 M €	-686%	-392,9 k €	-237%	-116,6 k €
Operating result	-14,2 M €	+3.7%	-14,7 M €	-51.0%	-9,8 M €	+0.6%	-9,8 M €	-51.5%	-6,5 M €	-110%	-3,1 M €	-686%	-392,9 k €	-237%	-116,6 k €
Net result	-9,6 M €	+17.9%	-11,7 M €	-38.8%	-8,4 M €	+10.2%	-9,4 M €	-44.9%	-6,5 M €	-113%	-3,1 M €	-676%	-393,3 k €	-237%	-116,7 k €
Balance sheet
Equity	244,1 M €	-3.8%	253,7 M €	+38.4%	183,3 M €	+89.2%	96,9 M €	+42.7%	67,9 M €	+926%	6,6 M €	+4877%	133,0 k €	+245%	-91,7 k €
Total assets	251,3 M €	-2.8%	258,7 M €	+37.1%	188,7 M €	+86.3%	101,3 M €	+37.2%	73,8 M €	+886%	7,5 M €	+2147%	333,0 k €	+1716%	18,3 k €
Cash	73,0 M €	+195%	24,8 M €	-79.7%	121,9 M €	+354%	26,9 M €	-49.0%	52,7 M €	+619%	7,3 M €	+2156%	324,8 k €	+1693%	18,1 k €
Debts	5,7 M €	+39.9%	4,1 M €	-2.4%	4,2 M €	+85.7%	2,3 M €	-60.0%	5,6 M €	+553%	864,2 k €	+332%	200,0 k €	+81.8%	110,0 k €
Other
Workforce	52,0 ETP	+27.1%	40,9 ETP	+111%	19,4 ETP	+92.1%	10,1 ETP	+166%	3,8 ETP	+280%	1,0 ETP		–		–

Estimate

Indicative valuation

As an indication, this company is worth

between 100 M€ and 250 M€

See the valuation

Governance

Board of directors

Seen on filing of 31/12/2025 · 7 active · 37 ended

Active mandates

Colin Bond

Director · since 15 novembre 2024 · until 28 mai 2030

Active

David Epstein

Director · since 08 juillet 2024 · until 28 mai 2030

Active

Angelika Martha Jahreis

Director · since 10 octobre 2023 · until 09 octobre 2029

Active

Felice Verduyn - van Weegen

Director · since 10 octobre 2023 · until 24 avril 2029

Active

Xiaoming Fang

Director · since 10 octobre 2023 · until 16 janvier 2026

Active

Tim Knotnerus

Managing director · since 05 mars 2021 · until 04 mars 2027

Active

Ohad Hammer

Director · since 14 mars 2019 · until 26 mai 2026

Active

Ended mandates

Colin Bond

Director · since 15 novembre 2024 · until 23 avril 2030

Ended

David Epstein

Director · since 08 juillet 2024 · until 23 avril 2030

Ended

Angelika Martha Jahreis

Director · since 10 octobre 2023 · until 24 avril 2029

Ended

Felice Isabel van Weegen

Director · since 10 octobre 2023 · until 24 avril 2029

Ended

At this address

Other companies at this address

Company	CBE no.
Science at Work Staffing België● Active	0748.569.982
THE HOUSE OF DEVELOPMENT● Active	0547.666.948

Annual accounts

Full financial information

	2025	2024	2023	2022	2021	2020
Type of account	Full model	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model
Start of the financial year	01/01/2025	01/01/2024	01/01/2023	01/01/2022	01/01/2021	01/01/2020
Closing of the financial year	31/12/2025	31/12/2024	31/12/2023	31/12/2022	31/12/2021	31/12/2020
Length of the financial year	12 months	12 months	12 months	12 months	12 months	12 months
Filing date	23/06/2026	03/06/2025	27/06/2024	03/07/2023	29/06/2022	24/05/2021
General meeting	26/05/2026	30/05/2025	28/05/2024	30/06/2023	15/06/2022	27/04/2021
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Ratios

Financial ratios

Looking for more information about this company?

Try for 7 days

Filings

Annual accounts filings

9 filings with the NBB

Model	Closing	General meeting	Filed	Language	Document
Full model	31/12/2025	26/05/2026	23/06/2026	Dutch	PDF
Abridged model	31/12/2024	30/05/2025	03/06/2025	Dutch	PDF
Abridged model	31/12/2023	28/05/2024	27/06/2024	Dutch	PDF
Abridged model	31/12/2022	30/06/2023	03/07/2023	Dutch	PDF
Abridged model	31/12/2021	15/06/2022	29/06/2022	Dutch	PDF
Abridged model	31/12/2020	27/04/2021	24/05/2021	Dutch	PDF
Abridged model	31/12/2019	28/04/2020	18/05/2020	Dutch	PDF
Micro model	31/12/2018	26/06/2019	11/07/2019	Dutch	PDF
Micro model	31/12/2017	24/04/2018	13/05/2018	Dutch	PDF

Estimate

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 100 M€ and 250 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Governance

Board of directors

Seen on filing of 31/12/2025 · 7 active · 37 ended

Active mandates

Colin Bond

Director · since 15 novembre 2024 · until 28 mai 2030

Active

David Epstein

Director · since 08 juillet 2024 · until 28 mai 2030

Active

Angelika Martha Jahreis

Director · since 10 octobre 2023 · until 09 octobre 2029

Active

Felice Verduyn - van Weegen

Director · since 10 octobre 2023 · until 24 avril 2029

Active

Xiaoming Fang

Director · since 10 octobre 2023 · until 16 janvier 2026

Active

Tim Knotnerus

Managing director · since 05 mars 2021 · until 04 mars 2027

Active

Ohad Hammer

Director · since 14 mars 2019 · until 26 mai 2026

Active

Ended mandates

Colin Bond

Director · since 15 novembre 2024 · until 23 avril 2030

Ended

David Epstein

Director · since 08 juillet 2024 · until 23 avril 2030

Ended

Angelika Martha Jahreis

Director · since 10 octobre 2023 · until 24 avril 2029

Ended

Felice Isabel van Weegen

Director · since 10 octobre 2023 · until 24 avril 2029

Ended

Shareholders

Ownership and network

Looking for more information about this company?

Try for 7 days

Belgian Official Gazette

Belgian Official Gazette publications

Mandates19/06/2026
ONTSLAGEN - BENOEMINGEN
PDF
Capital / shares17/04/2026
STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - KAPITAAL - AANDELEN
PDF
Capital / shares08/04/2026
STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - KAPITAAL - AANDELEN
PDF
Mandates11/03/2026
ONTSLAGEN - BENOEMINGEN
PDF
Capital / shares26/02/2026
STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - KAPITAAL - AANDELEN
PDF
Mandates17/06/2025
ONTSLAGEN - BENOEMINGEN
PDF
Mandates19/11/2024
STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - KAPITAAL - AANDELEN - ONTSLAGEN - BENOEMINGEN
PDF
Mandates18/07/2024
DIVERSEN - ONTSLAGEN - BENOEMINGEN
PDF

Source: Belgian Official Gazette

Competition

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

26/05/2026
reconductionOhad Hammer — bestuurder
26/05/2026
reconductionTim Knotnerus — bestuurder
12/03/2026
augmentation_capital
04/03/2026
augmentation_capital
16/01/2026
unknownAngelika Martha Jahreis — Onafhankelijk Bestuurder
16/01/2026
unknownColin Bond — Onafhankelijk Bestuurder
16/01/2026
unknownDavid Epstein — Voorzitter Bestuurder en Onafhankelijk Bestuurder
16/01/2026
unknownFelice Isabel Verduyn - Van Weegen — Klasse C Investeerder Bestuurder
16/01/2026
unknownOhad Hammer — Klasse A Investeerder Bestuurder
16/01/2026
unknownTim Knotnerus — CEO Bestuurder
15/01/2026
augmentation_capital
2025
Annual accounts 2025-9,6 M €↑
30/05/2025
reconductionOhad Hammer — Klasse A Investeerder Bestuurder
2024
Annual accounts 2024-11,7 M €↓
04/11/2024
augmentation_capital
08/07/2024
nominationDavid Epstein — Voorzitter Bestuurder
28/05/2024
reconductionPwC Bedrijfsrevisoren BV — commissaris
28/05/2024
reconductionOhad Hammer — Klasse B Investeerder Bestuurder
28/05/2024
reconductionJohn Haurum — Voorzitter Bestuurder en Onafhankelijk Bestuurder
2023
Annual accounts 2023-8,4 M €↑
2022
Annual accounts 2022-9,4 M €↓
2021
Annual accounts 2021-6,5 M €↓
2019
Annual accounts 2019-3,1 M €↓
2018
Annual accounts 2018-393,3 k €↓
2017
Annual accounts 2017-116,7 k €
13/04/2017
IncorporationPublic limited company

10/15	1 240 000	1 180 000	1 050 000
70	8 630 000	8 120 000	7 940 000
9904	412 000	388 000	301 000
17/49	2 970 000	3 140 000	3 380 000
9087	24,3	23,1	21,8

AgomAb Therapeutics

Overview

What does AgomAb Therapeutics do?

Trend over 8 financial years

Indicative valuation

Board of directors

Other companies at this address

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline